Clinical Trial

Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking

The Company Showed a Substantial Reduction in the Physical, Negative Characteristics that Accompany Heavy Drinking in its Recent Groundbreaking, Clinical…

1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…

1 year ago

ORYZON to Provide Corporate Progress Updates at Several Events in September

German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE,…

1 year ago

Safety Shot Announces Partnership with Digital Growth Platform VENDO

As Masters in the E-Commerce Space VENDO is Anticipated to Significantly Help to Grow the Safety Shot Brand Online. JUPITER,…

1 year ago

Veeva Announces Fiscal 2025 Second Quarter Results

Total Revenues of $676.2M, up 15% Year Over Year;Subscription Services Revenues of $561.3M, up 19% Year Over Year PLEASANTON, Calif.,…

1 year ago

Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,…

1 year ago

Breakthrough Technology Proves Rapid Relief of Depression With Non-Invasive Brain Stimulation

MINERAL WELLS, TX / ACCESSWIRE / August 28, 2024 / Depression, a debilitating disorder affecting millions worldwide, may soon be…

1 year ago

CORRECTING and REPLACING OMNY Health Launches Dynamic GLP-1 Network of 600,000+ Patients to Fuel Clinical Research on Its Use

New Studies on the Use of These Medications in Adult and Pediatric Populations are Supported by the Data NetworkATLANTA--(BUSINESS WIRE)--Please…

1 year ago

EydisBio Awarded $2.6 Million Grant to Advance TAK1 Inhibitor Program for Systemic Sclerosis

DURHAM, N.C., Aug. 28, 2024 /PRNewswire/ -- EydisBio, an early-stage pharmaceutical company leveraging a novel approach to treating various autoimmune…

1 year ago

Metabolon and the Scottish Early Rheumatoid Arthritis (SERA) Study Announce Partnership to Leverage Metabolomics Data to Better Understand the Molecular Mechanisms of Rheumatoid Arthritis

Partnership seeks to identify rheumatoid arthritis biomarkers to improve understanding of disease risk, progression, and treatment responses MORRISVILLE, N.C. and…

1 year ago